Recent News

Dynavax Presents at the Wedbush Life Sciences Conference
August 3, 2010

Dynavax Reports 2010 Second Quarter Financial Results
July 30, 2010

Dynavax to Present at the Wedbush Life Sciences Conference
July 28, 2010

Dynavax Promotes J. Tyler Martin, M.D. to President
July 27, 2010

Dynavax Completes Enrollment and First Immunizations in Universal Flu Vaccine Study
July 27, 2010

Dynavax Reports New Employment Inducement Awards
July 23, 2010

Dynavax Appoints Daniel Kisner, M.D. to Board of Directors
July 22, 2010

Dynavax Initiates First Human Trial in Universal Flu Vaccine Program
July 7, 2010

Dynavax Awarded NIH Grant to Explore Feasibility of Universal Papilloma Virus Vaccine
July 6, 2010

More...

Clinical-Stage Pipeline

Our clinical-stage pipeline includes 3 product candidates for the prevention and treatment of infectious diseases. More...

Focused on Infectious Diseases

Scientific expertise and proprietary technologies drive our discovery and development of novel Toll-like Receptor (TLR) based product candidates.  Our focus is on serious medical needs in the prevention and treatment of infectious diseases.  

Leading Partners

Our partnerships with leading pharmaceutical companies, including GlaxoSmithKline, AstraZeneca, and Novartis, and our funding agreements support our commitment to discover and develop TLR-based products to address serious medical needs.

Integrated European Subsidiary

Rhein Biotech, our European subsidiary, manufactures hepatitis B surface antigen for our lead product HEPLISAV hepatitis B vaccine. With 20 years in business, Rhein Biotech also provides integrated product development services to enable its partners to bring products to market.